Company
CytoMed Therapeutics Ltd (GDTC)
Standardized SEC financial data for CytoMed Therapeutics Ltd — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001873093 · NASDAQ · Pharmaceutical Preparations.
Revenue growth (YoY)
366.7%
Return on equity
-61.1%
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $70K | $324K |
| R&D expense | $1.0M | $1.1M | $1.5M | $1.6M | $1.9M | $2.2M |
| Interest expense | $106K | $118K |
Standardized from CytoMed Therapeutics Ltd's SEC filings — per-share figures split-adjusted. Full history via the API.
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Goodwill | — | $355 | $355 | $355 | $355 | $355 |
| Total assets |
Get GDTC data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/GDTC/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/GDTC/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"